Abstract
Current lung cancer screening protocols use low-dose computed tomography scans in selected high-risk individuals. Unfortunately, utilization is low, and the rate of false-positive screens is high. Peripheral biomarkers carry meaningful promise in diagnosing and monitoring cancer with added potential advantages reducing invasive procedures and improving turnaround time. Herein, the use of such blood-based assays is considered as an adjunct to further utilization and accuracy of lung cancer screening.
Original language | English (US) |
---|---|
Pages (from-to) | 411-419 |
Number of pages | 9 |
Journal | Thoracic surgery clinics |
Volume | 33 |
Issue number | 4 |
DOIs | |
State | Published - Nov 1 2023 |
Keywords
- Disease monitoring
- Liquid biopsy
- Low-dose computed tomography scan
- Lung cancer screening
ASJC Scopus subject areas
- General Medicine